Trinity Biotech PLC (NASDAQ: TRIB) and DBV Technologies (NASDAQ:DBVT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitabiliy, institutional ownership, risk and dividends.

Risk & Volatility

Trinity Biotech PLC has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Insider and Institutional Ownership

66.3% of Trinity Biotech PLC shares are owned by institutional investors. Comparatively, 48.2% of DBV Technologies shares are owned by institutional investors. 12.7% of Trinity Biotech PLC shares are owned by company insiders. Comparatively, 15.3% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Trinity Biotech PLC and DBV Technologies’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Trinity Biotech PLC $99.63 million 1.33 $7.90 million ($3.61) -1.66
DBV Technologies $8.60 million 231.28 -$130.95 million N/A N/A

Trinity Biotech PLC has higher revenue and earnings than DBV Technologies.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Trinity Biotech PLC and DBV Technologies, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech PLC 0 1 0 0 2.00
DBV Technologies 0 0 8 0 3.00

DBV Technologies has a consensus price target of $48.80, suggesting a potential upside of 12.86%. Given DBV Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than Trinity Biotech PLC.


This table compares Trinity Biotech PLC and DBV Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trinity Biotech PLC -98.39% 5.00% 2.63%
DBV Technologies N/A N/A N/A


DBV Technologies beats Trinity Biotech PLC on 7 of the 12 factors compared between the two stocks.

About Trinity Biotech PLC

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company’s product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with's FREE daily email newsletter.